Synageva BioPharma Corp

Synageva BioPharma — Merger or Acquisition (June 2015)

31 slides from Synageva BioPharma's merger presentation, Jun 5, 2015

  1. Slide 1: Rule 425 filing legend: Alexion internal website pages

    The following webpages appear on Alexion Pharmaceuticals, Inc.’s internal website Filed by Alexion Pharmaceuticals, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14a - 12 of the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. C

  2. Slide 2: A View to Synageva Integration Planning

    A View to Synageva Integration Planning Dan Bazarko, Vice President, Audit Synageva Integration Planning Team Leader Thanks for taking time to visit this page. On behalf of the integration planning team for the Synageva acquisition, we appreciate the support and the efforts of those of you who are i

  3. Slide 3: Atrium page: integration updates and contact restrictions

    This Atrium page has been designed to keep you up to date about the integration, and provide links to key resources and news. One question that we have heard recently is whether we can call or email our Synageva counterparts. In light of legal and regulatory considerations prior to closing, it’s imp

  4. Slide 4: Forward-Looking Statements

    Forward - Looking Statements This communication includes statements that may be forward - looking statements. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward - looking statements. Alexion and Synageva caution that these forward

  5. Slide 5: Additional Information about the Tender Offer

    Investors and security holders of Synageva are urged to read the tender offer statement on Schedule TO, filed on May 22, 2015 (as may be amended, the “Schedule TO”), the Registration Statement on Form S - 4, as filed on May 22, 2015 (as may be amended, the “Registration Statement”), and the solicita

  6. Slide 6: Global Town Hall May 6, 2015

    Global Town Hall May 6, 2015 The following presentation was made available to Alexion Pharmaceuticals, Inc. personnel on the company’s internal website.

  7. Slide 7: Few have taken a company from single to multi-product

    7 Few have ... taken a company from single to multi - product ... grown a company from $2B to $10B in revenue ... been at a company growing from 2,400 employees to 5,000 - 10,000 employees ... taken a company that has grown by 1644% in past 9 years and then tripled the value from there

  8. Slide 8: Soliris and Strensiq

    Soliris (eculizumab) {300 mg/30 mL [10 mg/ml) ‘SINGLE-USE VIAL = Z> —— Soliris (eculizumab) \ q Stensiq™ (ast u Solution for Ie evignunace honumasd ; f Hot a 29M , HPP SINGLE-USE VIAL Bonly

  9. Slide 9: Alexion stock price: October 2006 - October 2007

    9 Alexion stock price: October 2006 - October 2007 March 2007 : Soliris Approved for PNH; Stock gains 7.4% July 2007: Q2 Sales Results (first full PNH quarter); Stock gains 17.5% October 2007: Q3 Sales Results (2 nd full PNH quarter); Stock gains 10.3%

  10. Slide 10: Vision, a lot of hard work, some luck along the way

    10 Vision, a lot of hard work, some luck along the way • Limited resources • No clear development plan • No clear regulatory path • No clear path for commercialization • Courage to change the world

  11. Slide 11: Alexion: Global Leader in Rare Diseases

    11 Alexion: Global Leader in Rare Diseases • Kanuma ( sebelipase alfa) for LAL Deficiency aligns with our exclusive focus on bringing transformative therapies to patients suffering from under - diagnosed , devastating and rare diseases, such as PNH, aHUS and HPP Exclusive Focus on Life - Transformin

  12. Slide 12: Synageva BioPharma: Ideal Strategic and Operational Fit

    12 Synageva BioPharma: Ideal Strategic and Operational Fit • Patient - centric culture • Focus on discovering, developing and delivering medicines for patients with rare and devastating diseases Exclusive Focus on Rare Diseases • Kanuma under review for the treatment of patients with LAL Deficiency

  13. Slide 13: Synageva's Pipeline will Strengthen and Broaden Alexion's Portfolio

    13 Synageva’s Pipeline will Strengthen and Broaden Alexion’s Clinical and Preclinical Portfolio Source: Synageva Investor Presentation, April 2015 • Pipeline of rare disease assets • Highly innovative late - stage product, Kanuma (sebelipase alfa) • Expression platform to develop novel and next gene

  14. Slide 14: LAL-D is an Ideal Fit for Alexion's Exclusive Focus

    14 LAL - D is an Ideal Fit for Alexion’s Exclusive Focus on Treating Patients with Devastating and Rare Diseases Sources: Hillmen P, Lewis SM, Bessler M et al. N Engl J Med. 1995; 333:1253 - 1258; Caprioli, J., et al. Blood. 2006; 108:1267 - 12 79; Whyte et al. Poster presented at the 2014 PAS Meeti

  15. Slide 15: Kanuma Aligned with Alexion's Portfolio of Life-Transforming Therapies

    15 Kanuma, an Investigational Treatment for LAL - D, is Aligned with Alexion’s Portfolio of Life - Transforming Therapies Sources: Hill A et al. Presented at the Annual ASH Meeting December, 2012; Johnson et al. Presented at ERA - EDTA Congress , May, 2014; Licht C et al. ASH 2012. Poster 985; Whyte

  16. Slide 16: Alexion's Proven Track Record in Identifying Patients

    16 Alexion’s Proven Track Record in Identifying Patients with Underdiagnosed, Devastating and Rare Diseases PNH Annual Newly Identified PNH Patients in Core Markets Alexion’s PNH diagnostic initiatives have enabled the company to identify a similar number of new PNH patients annually since the Solir

  17. Slide 17: PNH and aHUS Diagnostic Expertise Leveraged for HPP and LAL-D

    17 Alexion’s PNH and aHUS Diagnostic Expertise will be Leveraged for Our HPP and LAL - D Patient Identification Initiatives PNH aHUS HPP LAL - D Driving Diagnosis Across Multiple Rare Diseases Soliris for PNH Soliris for aHUS Hematology & Nephrology Franchise Strensiq for HPP Kanuma for LAL - D Meta

  18. Slide 18: Alexion to Maximize Synageva's Value Across 50-Country Platform

    18 Alexion to Maximize Synageva’s Value, Leveraging Our Expertise Across Our 50 - Country Platform • Leverage our 50 - country platform and expand Alexion’s metabolic franchise to launch Kanuma • Utilize Alexion’s global regulatory expertise to secure approvals in all key markets • Secure worldwide

  19. Slide 19: Kanuma Will Further Accelerate and Diversify Revenues

    19 Following Approval, Kanuma w ill Further Accelerate and Diversify Our Strong, Consistently Growing Revenues Across Our 50 - Country Platform Revenues in 2016 – 2020 are illustrative and should not be taken as guidance * $2,1465M excludes ~$88M in prior years’ sales in France ; ‡ Midpoint of FY15

  20. Slide 20: Metabolic Franchise: Anticipated Launches in 2015

    20 METABOLIC FRANCHISE Anticipated Launches in 2015 PRECLINICAL CLINICAL DEVELOPMENT REGISTRATION FILINGS Alexion Program Synageva Program cPMP MoCD Type A Strensiq HPP Asfotase Alfa NF - 1 SBC - 105 GACI/Other Undisclosed Preclinical #6 SBC - 103 MPSIIIB mRNA Therapies #1 Kanuma LAL - D Undisclosed

  21. Slide 21: Creating the Most Robust Rare Disease Pipeline in Biotech

    21 Creating the Most Robust Rare Disease Pipeline in Biotech PRECLINICAL EARLY CLINICAL DEVELOPMENT ADVANCED CLINICAL DEVELOPMENT REGISTRATION FILINGS MARKETED Soliris Next Gen Inflammatory Metabolic Undisclosed Synageva Complement Inhibition Soliris DGF ALXN1007 APS Complement Inhibitor (4) ALXN550

  22. Slide 22: Ambitions for Tomorrow

    Ambitions for Tomorrow • Global leader in developing, manufacturing and commercializing the most innovative portfolio of complement inhibitors • Multiple therapeutic areas independent of complement • Most innovative R&D in biotech industry • World - class capability in manufacturing the highest qual

  23. Slide 23: The Alexion Way

    The Alexion Way • Setting the highest patient - centric ambitions • Never settling for conventional plans and timelines • Self - critical discipline • Insatiable thirst for doing better • Turning “No” into “Yes”

  24. Slide 24: Questions

    Questions BioPharma

  25. Slide 25: Forward-Looking Statements

    Confidential – For Internal Use Forward - Looking Statements This communication includes statements that may be forward - looking statements. The words “believe,” “expect,” “anticipate,” “pro ject” and similar expressions, among others, generally identify forward - looking statements. Alexion and Sy

  26. Slide 26: Additional Information about the Tender Offer

    Confidential – For Internal Use Investors and security holders of Synageva are urged to read the tender offer statement on Schedule TO, filed on May 22, 2015 (a s may be amended, the “Schedule TO”), the Registration Statement on Form S - 4, as filed on May 22, 2015 (as may be amended, the “Registrat

  27. Slide 27: Synageva Acquisition Integration Planning - Success Criteria

    Confidential – For Internal Use Synageva Acquisition Integration Planning – Success Criteria The following presentation was made available to Alexion Pharmaceuticals, Inc. personnel on the company’s internal website.

  28. Slide 28: Overview

    Confidential – For Internal Use Overview • We do not own Synageva until the transaction closes • We are separate companies and must operate as separate companies • Synageva Information is CONFIDENTIAL and subject to CDA • Merger Agreement requires that access to Synageva must be directed to a Synage

  29. Slide 29: Integration Success Criteria

    Confidential – For Internal Use 3 Success Criteria Integration Success Criteria x No disruption of current operations x Flawless launches of new products x Achieve projected revenue targets x Retain critical employees and key partners x Maintain reputation within marketplace x Transfer knowledge eff

  30. Slide 30: Forward-Looking Statements

    Confidential – For Internal Use 4 Forward - Looking Statements This communication includes statements that may be forward - looking statements. The words “believe,” “expect,” “anticipate,” “pro ject” and similar expressions, among others, generally identify forward - looking statements. Alexion and

  31. Slide 31: Additional Information about the Tender Offer

    Confidential – For Internal Use Investors and security holders of Synageva are urged to read the tender offer statement on Schedule TO, filed on May 22, 2015 (a s may be amended, the “Schedule TO”), the Registration Statement on Form S - 4, as filed on May 22, 2015 (as may be amended, the “Registrat

Synageva Biopharma — Merger or Acquisition (June 2015) on 6ix